BIONEER Corporation

Article 15, 3(c) the post-market surveillance obligations are complied with in accordance with Article 10(9), Article 15, 3(e) in the case of devices for performance studies intended to be used in the context of interventional clinical performance studies or other performance studies involving risks for the subjects, the statement referred to in Section 4.1 of Annex XIV is issued.

Article 15, 3(c) the post-market surveillance obligations are complied with in accordance with Article 10(9), Article 15, 3(e) in the case of devices for performance studies intended to be used in the context of interventional clinical performance studies or other performance studies involving risks for the subjects, the statement referred to in Section 4.1 of Annex XIV is issued.

Article 15, 3(a) the conformity of the devices is appropriately checked, in accordance with the quality management system under which the devices are manufactured, before a device is released

Article 15, 3(a) the conformity of the devices is appropriately checked, in accordance with the quality management system under which the devices are manufactured, before a device is released

Article 15, 3(c) the post-market surveillance obligations are complied with in accordance with Article 10(9), Article 15, 3(e) in the case of devices for performance studies intended to be used in the context of interventional clinical performance studies or other performance studies involving risks for the subjects, the statement referred to in Section 4.1 of Annex XIV is issued.